Medpace Holdings, Inc. $MEDP is Nutshell Asset Management Ltd’s 10th Largest Position

Nutshell Asset Management Ltd lessened its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 54.3% during the third quarter, Holdings Channel.com reports. The fund owned 18,712 shares of the company’s stock after selling 22,217 shares during the period. Medpace accounts for 4.6% of Nutshell Asset Management Ltd’s holdings, making the stock its 10th largest holding. Nutshell Asset Management Ltd’s holdings in Medpace were worth $9,621,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Norges Bank purchased a new stake in shares of Medpace during the second quarter worth about $66,597,000. Clarkston Capital Partners LLC bought a new stake in shares of Medpace in the second quarter worth about $40,569,000. Mawer Investment Management Ltd. increased its holdings in Medpace by 17.4% during the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after purchasing an additional 121,213 shares during the period. Bares Capital Management Inc. raised its position in Medpace by 319.2% during the 2nd quarter. Bares Capital Management Inc. now owns 157,084 shares of the company’s stock valued at $49,302,000 after purchasing an additional 119,608 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Medpace by 79.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 265,270 shares of the company’s stock valued at $83,258,000 after purchasing an additional 117,301 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

NASDAQ:MEDP opened at $470.59 on Monday. The firm has a market capitalization of $13.36 billion, a P/E ratio of 30.76, a PEG ratio of 2.26 and a beta of 1.44. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $628.92. The company’s 50-day simple moving average is $533.94 and its 200 day simple moving average is $539.47.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. During the same period last year, the business earned $3.67 earnings per share. The business’s revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on MEDP. Barclays raised Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 target price on the stock in a research note on Friday. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Mizuho set a $582.00 price target on shares of Medpace in a report on Wednesday, February 11th. Leerink Partners reduced their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. Finally, TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and decreased their price objective for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. Five analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Medpace currently has an average rating of “Hold” and a consensus target price of $486.67.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.